Treatment News : Both Viread and Reyataz Lead to Greater Bone Density Loss

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 31, 2011

Both Viread and Reyataz Lead to Greater Bone Density Loss

Truvada (tenofovir plus emtricitabine) was associated with greater bone loss than Epzicom (abacavir plus lamivudine), according to a study published in the June 15 issue of The Journal of Infectious Diseases. The same study found that Reyataz (atazanavir) was associated with greater bone loss than Sustiva (efavirenz), and that these differences held up even when accounting for classic risk factors for changes in bone density.

Reduction in bone mineral density (BMD)—called osteopenia when it is mild and osteoporosis when more severe—has been reported at higher rates in people living with HIV than in their HIV-negative counterparts in multiple studies. This is particularly true of younger HIV-positive men.

Multiple studies have also shown that most people with HIV have minor to moderate bone loss (between 2 and 6 percent) in general within the first two years of starting antiretroviral (ARV) treatment, but this loss is not generally progressive after the first two years. Although several studies have suggested that the tenofovir in Viread, Truvada and Atripla may cause a greater degree of bone loss than other drugs from the same class, no studies have compared Reyataz with Sustiva—both popular first-line treatment options in combination with Truvada or Epzicom—in terms of bone density changes.

Grace McComsey, MD, from Case Western Reserve University in Cleveland, and her colleagues set out to do just that. They compared bone density scans—called dual energy X-ray absorptiometry (DEXA) scans—from 271 HIV-positive people enrolled in the AIDS Clinical Trials Group (ACTG) 5202 study. ACTG 5202 was a four-way comparison of four different ARVs: Viread, Ziagen, Reyataz and Sustiva.

All four groups were similar in terms of their demographics and health. Most of the participants were in their late 30s, and roughly 60 percent were male. All four groups were racially diverse and were of normal body weight. About one quarter had osteopenia of both the spine and waist before starting treatment. On average, less than 8 percent had osteoporosis of the lower spine, and less than 2 percent had osteoporosis of the hip.

On average, loss of bone density was generally mild to moderate, with an average loss of about 3 percent during the first year. There was a slight rise in bone density after the first year, so that over the course of two years, the average loss had diminished to 2.3 percent.

The team found, however, that those taking Truvada had a significantly greater loss of bone density in the spine than those taking Epzicom (3.3 percent versus 1.3) and also in the hip (4 percent versus 2.6 percent). As for Reyataz and Sustiva, loss of bone density in the hip was similar between the two treatments, but those taking Reyataz had greater loss of bone in the spine (3.1 percent versus 1.7 percent). Overall, when Sustiva or Reyataz were paired with Truvada, those participants had a greater degree of BMD loss than those whose Sustiva or Reyataz was paired with Epzicom.

While these losses of bone density may not seem large, the authors note that “the degree of BMD loss [overall, and the difference between treatment groups] should not be perceived as clinically insignificant. Indeed, these decreases are similar in magnitude to the BMD losses sustained during the first [two] years of menopause.”

McComsey and her colleagues hypothesize that the cause of the BMD loss on treatment likely differs between nucleoside reverse transcriptase inhibitors (for example, Truvada), non-nucleoside reverse transcriptase inhibitors (such as Sustiva) and protease inhibitors (such as Reyataz). The researchers conclude: “Studies investigating the mechanisms behind the bone loss with ART initiation are needed.”

Search: Viread, Reyataz, Truvada, tenofovir, emtricitabine, abacavir, Epzicom, lamivudine, Sustiva, efavirenz, Grace McComsey, Case Western Reserve University, Cleveland, ACTG 5202, bone mineral density, BMD, osteoporosis, osteopenia, DEXA

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.